Marketed as “topical Botox”, and the mechanism is a real one, borrowed honestly: the sequence mimics the N-terminal end of SNAP-25, a SNARE protein required for vesicle fusion at the neuromuscular junction. By competing for a position in the SNARE complex it is proposed to destabilise assembly and reduce acetylcholine release, softening muscle contraction. Botulinum toxin cleaves SNAP-25 outright; this competes with it — a far weaker intervention.
The honest limitation is delivery, not mechanism. It is a charged hydrophilic hexapeptide, and the stratum corneum is a formidable barrier to exactly that kind of molecule. Manufacturer-sponsored studies report modest wrinkle-depth reductions; independent evidence is thinner, and how much peptide reaches the neuromuscular junction of a facial muscle through intact skin is the question the marketing does not address.
A cosmetic ingredient, requiring no FDA pre-approval. Cosmetic status permits appearance claims only. A product genuinely claiming to affect muscle function would be making a drug claim.
Topical use has a long commercial record and a benign safety profile. The realistic risk is disappointment rather than harm.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.